Last reviewed · How we verify
Recombinant human brain natriuretic peptide
At a glance
| Generic name | Recombinant human brain natriuretic peptide |
|---|---|
| Sponsor | Shanghai Zhongshan Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock (NA)
- Evaluation of the Efficacy of rhBNP in Patients With Diuretic Resistance After Cardiac Surgery (NA)
- Metabolic Effects of Natriuretic Peptide Hormones (PHASE4)
- Effect of Recombinant Human Brain Natriuretic Peptide on Ventricular Remodeling and Cardiac Function in Patients With Acute Anterior Myocardial Infraction Undergoing Percutaneous Coronary Intervention
- rhBNP in Type 3 Pulmonary Hypertension (PHASE4)
- Effect of rhBNP on CMD in Patients With STEMI After PPCI (NA)
- Preliminary Study on the Clinical Effect of Recombinant Human Brain Natriuretic Peptide on Sepsis Complicated With Heart Failure (NA)
- Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: